Rewind Therapeutics, founded by Axxam and CD3, focusing on myelin-related diseases, raises €15.2 million in Series A Financing Round

January 4th, 2018 – Milan (Italy) – Axxam is proud to announce that Rewind Therapeutics, a Belgian biotech company recently founded by Axxam itself and KU Leuven’s Centre for Drug Design and Discovery (CD3 – Leuven, Belgium), has completed a €15.2 million Series A round that will finance research programs directed towards the development of novel re-myelinating therapies for patients suffering from Multiple Sclerosis and other myelin-related diseases. The round was led by life science investors Boehringer Ingelheim Venture Fund (BIVF), Merck Ventures BV (MV) and Participatiemaatschappij Vlaanderen (PMV), together with CD3 and KU Leuven Gemma Frisius Fonds (GFF).  For more info please open the Press Release from Rewind Therapeutics.

Open PDF document